Evidence map›Paper›PMID 39412611›Full record

SynthesisHepatology international2024

Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.

Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George

Abstract readSystematic Review
In one paragraph

Synthesis in Hepatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maito SuohStorr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.
Saeed EsmailiStorr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.
Mohammed EslamStorr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia.
Jacob GeorgeStorr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, 176 Hawkesbury Rd, Westmead, NSW, 2145, Australia. jacob.george@sydney.edu.au.ORCID http://orcid.org/0000-0002-8421-5476

Funding

Cancer Institute NSW 2021/ATRG2028National Health and Medical Research Council of Australia APP1053206National Health and Medical Research Council of Australia APP1107178National Health and Medical Research Council of Australia APP1108422National Health and Medical Research Council of Australia APP1196492National Health and Medical Research Council of Australia APP2001692
6 · The paper itself

Abstract

backgroundThe international consensus to revise non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 attracted significant attention. The impact of the MAFLD definition on the research community has not been objectively assessed. We conducted an analysis of systematically collected literature on MAFLD to understand its research impact.

methodsFrom PubMed, Web of Science, and Scopus, the literature adopting MAFLD, written in English, and published from 2020 to 10 October 2023 was collected. The publication metrics, including publication counts, publishing journals, author countries, author keywords, and citation information, were analyzed to evaluate the research impact and key topics on MAFLD.

results1469 MAFLD-related papers were published in 434 journals with a steady increase in the number. The intense publishing and citations activity on MAFLD indicates the large impact of the redefinition. Topic assessment with keyword and citation analysis revealed a transition from the proposal and discussion of the redefinition to clinical characterization of MAFLD with a focus on metabolic dysfunction. Moreover, the diagnostic criteria for MAFLD showed better performance in predicting hepatic and extrahepatic outcomes compared to NAFLD. The publications were from 99 countries with evidence of strong regional and global collaboration. Multiple international societies and stakeholders have endorsed MAFLD for its utility in clinical practice, improving patient management and promoting multidisciplinary care, while alleviating stigma.

conclusionThis survey provides a quantitative measure of the considerable international impact and contributions of the MAFLD definition towards liver research and as part of the spectrum of cardiometabolic disorders.

Indexed as

Non-alcoholic Fatty Liver DiseaseBibliometricsBiomedical ResearchHumansBibliographic networkBibliometric analysisBibliometricsCardiovascular diseaseChronic kidney diseaseCo-citation networkCo-occurrence networkCOVID-19Liver fibrosisMAFLD

Identifiers

PMID39412611
PMCPMC11632019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.